Bank of America
ACTU

Bank of America’s Actuate Therapeutics ACTU Stock Holding History

Bank of America’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,034
Closed -$30.2K – 5855
2026
Q1 		$30.2K Buy
11,034
+1,973
+22% +$8.17K ﹤0.01% 5635
2025
Q4 		$55.5K Buy
9,061
+4,189
+86% +$28.8K ﹤0.01% 5814
2025
Q3 		$32.6K Sell
4,872
-10,420
-68% -$75.5K ﹤0.01% 6953
2025
Q2 		$93.4K Buy
15,292
+15,267
+61,068% +$133K ﹤0.01% 6548
2025
Q1 		$169 Buy
25
+1
+4% +$8 ﹤0.01% 7729
2024
Q4 		$191 Buy
24
+1
+4% +$8 ﹤0.01% 7596
2024
Q3 		$171 Buy
+23
New +$182 ﹤0.01% 7607

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Bank of America's ACTU Position: Q2 2026 in Review

Bank of America sold out of Actuate Therapeutics (ACTU) in Q2 2026, closing a stake of 11,034 shares — an estimated $30.2K sold.

Bank of America first reported a position in ACTU in Q3 2024 and held it in 7 quarters. The position peaked at $93.4K in Q2 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Bank of America reported no remaining Actuate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of America sold 11,034 Actuate Therapeutics shares in Q2 2026, an estimated $30.2K.
  • Bank of America first reported a position in Actuate Therapeutics in Q3 2024 and held it in 7 quarters.
  • Bank of America's Actuate Therapeutics position peaked at $93.4K in Q2 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.